Adding Liraglutide to Capped Insulin Reduced HbA1c
Liraglutide plus capped insulin linked to reduced HbA1c, body weight, and insulin requirements.
(HealthDay News) — Liraglutide added to capped insulin is associated with reductions in glycated hemoglobin (HbA1c), body weight, and insulin requirements, according to a study published in Diabetes Care.
Bo Ahrén, MD, from Lund University in Sweden, and colleagues conducted a 26-week study to examine the efficacy and safety of liraglutide added to capped insulin doses. A total of 835 participants with type 1 diabetes were enrolled and randomly assigned in a 3:1 ratio to once-daily subcutaneous liraglutide (1.8 mg, 1.2 mg, and 0.6 mg) or placebo added to an individually capped daily dose of insulin.
The researchers observed a significant decrease in mean baseline HbA1c with liraglutide vs placebo at week 26 (−0.33%, −0.22%, and −0.23%, respectively, vs 0.01%). Liraglutide correlated with significant reductions in mean body weight vs placebo (−5.1 kg, −4.0 kg, and −2.5 kg, respectively, vs −0.2 kg).
For liraglutide vs placebo there were significant reductions in daily insulin dose and increases in quality of life. Higher rates of symptomatic hypoglycemia were seen for liraglutide 1.2 mg vs placebo (21.3 vs 16.6 events/patient/year; P=.03); there were higher rates of hyperglycemia with ketosis for liraglutide 1.8 mg vs placebo (0.5 vs 0.1 events/patient/year; P=.01).
"Liraglutide added to capped insulin reduced HbA1c, body weight, and insulin requirements but with higher rates of hypoglycemia for liraglutide 1.2 mg and hyperglycemia with ketosis for liraglutide 1.8 mg," the researchers wrote.
Disclosures: Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which manufactures liraglutide and funded the study.